Press Releases

Panama City, Panama, May 22, 2024 (GLOBE NEWSWIRE) -- Gate.io, a leading crypto exchange and Web3 innovator, has announced its 11th-anniversary celebrations, showcasing its milestones and launching prize-winning activities for its global user base. Since its founding in 2013, Gate.io has actively worked to create a secure and cutting-edge platform for cryptocurrency users worldwide. Under the leadership of Founder and CEO Dr. Lin Han, the platform has... (continue reading...)

HONG KONG, May 22, 2024 - (ACN Newswire) - - Kingsoft Corporation Limited ("Kingsoft" or the "Company"; HKEx stock code: 03888), a leading Chinese software and Internet service company, has Announces First Quarter Results for the Period Ended March 31, 2024.

In the first quarter of 2024, the revenue of Kingsoft increased 8% year-on-year to RMB2,136.9 million. Among them, revenue from the office software and services, and online games and others represented 57% and 43%... (continue reading...)

DALLAS--(BUSINESS WIRE)-- AECOM (NYSE: ACM), the world’s trusted infrastructure consulting firm, today announced it has been selected by the Regional Municipality of Peel (Peel Region) to provide design and engineering services for the expansion of the Clarkson Water Resource Recovery Facility (WRRF) in Ontario’s Peel Region. AECOM will be responsible for the design and implementation of the expansion, providing increased capacity and flexibility to accommodate... (continue reading...)

Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases

GENEVA, May 22, 2024 (GLOBE NEWSWIRE) -- Antion Biosciences (Antion), a Geneva-based cell and gene therapy company developing “off-the-shelf” cell therapies, announces the development of next generation anti-CD19 chimeric antigen receptor (CAR) T-cells for B-cell driven autoimmune diseases.

Autoimmunity affects up to 10% of the global population, and the overall burden of care... (continue reading...)

GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that dosing has been initiated in a Phase I study of the drug candidate IRL757. IRL757 has been shown in preclinical disease models to counteract apathy - a condition that impairs the quality of life... (continue reading...)